Genentech Backtracks In Synagis Dispute

Law360, New York (November 2, 2006, 12:00 AM EST) -- Genentech Inc. has pulled a complaint against biotech competitor MedImmune Inc. which alleged that MedImmune’s Synagis, used to stave off dangerous respiratory tract infections in infants, violated its patents.

As it wrangles with Genentech over a patent-license dispute over the same product before the U.S. Supreme Court, MedImmune said it had never received this complaint, according to a filing with the U.S. Securities and Exchange Commission on Wednesday. Genentech filed the complaint in January in the U.S. District Court for the Eastern District of Texas....
To view the full article, register now.